Contact the Desk

Editorial correspondence

Peptide Med Group takes correction seriously. If a citation is misquoted, a trial has published new results, or a regulatory status has changed, that correspondence improves the accuracy of the whole site and is read carefully.

The most useful submissions specify three things: the page in question, the exact passage being challenged, and the supporting reference — a DOI or PubMed ID where possible. That format lets a proposed change be checked against its source before anything is edited.

Editorial mailbox: editors@peptidemedgroup.com

What this desk cannot do

This is a literature digest, not a clinical service. It cannot advise on, or comment on, human use of any compound discussed here. It cannot recommend a dose, schedule, or route of administration for any individual. It cannot evaluate whether a cited trial's findings apply to a specific person's situation. It cannot help source, recommend, or locate any compound from any supplier.

Tirzepatide is a prescription medicine; readers should work with a licensed provider. Thymosin alpha-1 is not FDA-approved in the US. NAD+ and ipamorelin fall outside standard drug regulation entirely. Anyone seeking clinical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence aren't guaranteed and may be delayed.